Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

BioSpace

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals' Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Verte

Rare Disease

Read full story

pharminent June 5, 2026 (Last updated: June 5, 2026)

BioSpace

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Verte

Rare Disease

Read full story

Related Stories

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

Boehringer advances duo for aggressive cancers into phase 3

Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short

You May Have Missed

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

Replimune gets early August decision date for twice-rejected melanoma drug

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms